Piramal Pharma Solutions Expands Capacity for Sterile Manufacturing in Lexington
03 8월 2016 - 1:12AM
Business Wire
Piramal Pharma Solutions, a provider of sterile drug product
development and manufacturing services, has announced plans for a
$25 million expansion of its facilities in Lexington, Kentucky.
Piramal Pharma Solutions’ plan focuses on expanding the
Lexington site capabilities and capacity for commercial aseptic
manufacturing. This will be done by increasing vial filling
capability and lyophilisation capacity, as well as upgrades to the
associated facilities and utilities. Piramal’s Lexington site has a
strong pipeline of products which are expected to be commercialized
in next 3 to 5 years. Add to that the fast growing Sterile Market
in the US, recent consolidations in the CMO space and shut down of
many manufacturing sites in the US, has created a big demand for
quality manufacturers in the Sterile segment. The Sterile market in
the US and Europe is growing at a healthy rate of 11% and the
Contract Manufacturing in the Sterile Dosage Form is growing at 13%
year on year. Piramal believes that it can take advantage of the
market situation and grow it Lexington business multi-fold.
Phase 1 of the expansion of the Lexington facility will add a
new manufacturing suite including a high speed vial filling machine
that provides controlled/safe environment for handling potent
materials with an advantage of automated Vial Washing and
Sterilization. Also as part of the first phase of expansion,
Piramal will install a new isolator based vial filler in its
existing manufacturing suite, which is a newer technology and
considered much higher in quality standards. Combined, the two
fillers installed under Phase I of the expansion will increase the
company’s vial filling capabilities by more than five-fold. Phase 2
of the expansion will include the installation of two
state-of-the-art lyophilizers and are planned to integrate with the
new filler line in the new manufacturing suite offering dedicated
capacity for both potent and non-potent products
Vivek Sharma, CEO – Pharma Solutions, Piramal Enterprises,
commented: “Since our initial investment the Kentucky site has
demonstrated both leadership and growth, and we are pleased to
announce this next phase of investment to enhance capability and
capacity. We appreciate the active support from the State of
Kentucky, the local Government, and most importantly, the
community, as we continue our growth plans in Lexington. The
expansion in our capacity at Kentucky will help us better serve our
customers who are looking for us to deliver solutions that will
improve the standard of care.”
Bill Wedlake, President of Piramal Pharma Solutions
Formulations Business, added: “We are extremely excited to
initiate this expansion and continue the company’s vision of
becoming the premier aseptic manufacturing service provider that
began with the acquisition of Coldstream Laboratories in January of
2015.”
About Piramal Pharma Solutions
Piramal Pharma Solutions, the Contract Development and
Manufacturing arm of Piramal Enterprises Ltd., has assets across
North America, Europe and Asia and offers services across the
entire drug lifecycle – from development and commercial
manufacturing to off-patent supplies of API and formulations. In
2015, the division acquired Coldstream Laboratories in Kentucky, a
Contract Development and Manufacturing Organization focused on the
development and manufacturing of sterile injectable products. This
facility is a specialty pharmaceutical contract manufacturing
organization, also offering full analytical, and formulation,
microbiology, and lyophilization development services. Piramal
Pharma Solutions at Kentucky specializes in the development and
manufacture of highly potent compounds and operates as Kentucky’s
only parenteral manufacturing facility.
About Piramal Enterprises Limited
Piramal Enterprises Limited (PEL) is one of India’s large
diversified companies, with a presence in Healthcare, Healthcare
Information Management and Financial Services. PEL’s consolidated
revenues were around $ 1 billion in FY2016, with 61% of revenues
from outside India.
PEL is listed on the Bombay Stock Exchange and the National
Stock Exchange in India.
For more information, visit www.piramalpharmasolutions.com or
email Contactus@piramal.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160802006562/en/
For Media:Akansha PradhanCorporate Communications,Piramal
GroupTel: +91 22 3351 4082akansha.pradhan@piramal.comorFor
Investors:Hitesh Dhaddha,Investor Relations Team,Piramal
Enterprises LimitedTel: +91 (0) 22 6151
3430investor.relations@piramal.com
Morgan Stanley Propels S Propels S&P 500 Index (AMEX:PEL)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Morgan Stanley Propels S Propels S&P 500 Index (AMEX:PEL)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
